Scarica l'app Stockscreener
42.65
5.43%
-2.32
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GH Giù?
Forum
Previsione
Precedente Chiudi:
$44.97
Aprire:
$44.31
Volume 24 ore:
684.50K
Relative Volume:
0.31
Capitalizzazione di mercato:
$5.57B
Reddito:
$692.26M
Utile/perdita netta:
$-512.41M
Rapporto P/E:
-10.06
EPS:
-4.24
Flusso di cassa netto:
$-274.36M
1 W Prestazione:
-5.83%
1M Prestazione:
-7.75%
6M Prestazione:
+104.07%
1 anno Prestazione:
+164.64%
Intervallo 1D:
$42.04
$44.97
Intervallo di 1 settimana:
$42.04
$46.78
Portata 52W:
$16.77
$50.89
Guardant Health Inc Stock (GH) Company Profile
Nome
Guardant Health Inc
Settore
Industria
Telefono
855-698-8887
Indirizzo
3100 HANOVER STREET, PALO ALTO
Confronta GH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
42.59 | 5.57B | 692.26M | -512.41M | -274.36M | -4.24 |
|
TMO
Thermo Fisher Scientific Inc
|
418.79 | 169.62B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
182.65 | 138.06B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
407.79 | 32.79B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
99.50 | 29.99B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
138.15 | 26.61B | 15.41B | 1.37B | 2.11B | 7.50 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-01-23 | Iniziato | Barclays | Overweight |
| 2024-06-28 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-24 | Ripresa | Craig Hallum | Buy |
| 2023-12-14 | Iniziato | Guggenheim | Neutral |
| 2023-12-13 | Iniziato | Wolfe Research | Peer Perform |
| 2023-11-13 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-09-27 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-05-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-05-05 | Iniziato | UBS | Buy |
| 2023-03-09 | Downgrade | Citigroup | Buy → Neutral |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-11-01 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-10-19 | Iniziato | Craig Hallum | Buy |
| 2022-10-06 | Iniziato | Stephens | Overweight |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-06-03 | Iniziato | Piper Sandler | Overweight |
| 2022-04-28 | Ripresa | BTIG Research | Buy |
| 2022-02-24 | Reiterato | Canaccord Genuity | Buy |
| 2022-02-24 | Reiterato | Citigroup | Buy |
| 2022-02-24 | Reiterato | Cowen | Outperform |
| 2022-02-24 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-24 | Reiterato | SVB Leerink | Outperform |
| 2022-02-24 | Reiterato | Stifel | Buy |
| 2022-02-24 | Reiterato | Wells Fargo | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-06-15 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-03 | Iniziato | Goldman | Buy |
| 2021-05-25 | Iniziato | Wells Fargo | Overweight |
| 2021-01-11 | Iniziato | Stifel | Buy |
| 2020-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2020-06-12 | Iniziato | BTIG Research | Buy |
| 2020-02-21 | Iniziato | Guggenheim | Buy |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-08-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-04-16 | Iniziato | Canaccord Genuity | Buy |
| 2019-04-10 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-02-28 | Reiterato | BofA/Merrill | Neutral |
| 2018-10-29 | Iniziato | BofA/Merrill | Neutral |
| 2018-10-29 | Iniziato | JP Morgan | Overweight |
| 2018-10-29 | Iniziato | William Blair | Outperform |
Mostra tutto
Guardant Health Inc Borsa (GH) Ultime notizie
Guardant Health price target raised to $60 from $56 at BofA - Yahoo Finance
Guardant Health (GH) Price Target Increased by BofA Amid Sector Challenges | GH Stock News - GuruFocus
BofA Securities Raises Price Target on Guardant Health to $60 From $56, Keeps Buy Rating - marketscreener.com
Lobbying Update: $15,500 of GUARDANT HEALTH INC. lobbying was just disclosed - Quiver Quantitative
Guardant Health to Report First Quarter 2025 Financial Results o - GuruFocus
Circulating Cell-Free Tumor DNA Market Detailed In New Research - openPR.com
S&P 500 Futures Up in Premarket Trading; Guardant Health, Brookfield Wealth Solns Lead - Barron's
Guardant Health to Report First Quarter 2025 Financial Results on April 30, 2025 - The Joplin Globe
Mizuho Initiates Coverage of Guardant Health (GH) with Outperform Recommendation - MSN
Barclays Adjusts Guardant Health (GH) Price Target Amid Sector C - GuruFocus
Mizuho Initiates Guardant Health at Outperform - marketscreener.com
Guardant Health secures facility lease extension through 2031 By Investing.com - Investing.com Canada
‘Preparing For Regulatory Milestones, Commercial Launch’ Are Priorities, Says New Freenome CEO Aaron Elliott - insights.citeline.com
Guardant Health (GH) Receives Outperform Rating from Mizuho with Strong Growth Prospects | GH Stock News - GuruFocus
Guardant Health secures facility lease extension through 2031 - Investing.com
Reflecting On Testing & Diagnostics Services Stocks’ Q4 Earnings: Guardant Health (NASDAQ:GH) - Yahoo Finance
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.
Guardant Health partners with Bayshore for cancer tests in Canada By Investing.com - Investing.com South Africa
Guardant Health and Bayshore HealthCare Partner to Expand Access to Advanced Precision Oncology Testing in Canada - 01net
Guardant Health partners with Bayshore for cancer tests in Canada - Investing.com
Guardant Health And Bayshore Healthcare Partner To Expand Access To Advanced Precision Oncology Testing In Canada - MarketScreener
A More Convenient Way to Get Screened for Colon Cancer - Sunnyside Sun
(GH) Trading Advice - news.stocktradersdaily.com
4 Healthcare Stocks With Massive Gains—and More to Come - MarketBeat
Guardant Health’s Strategic Growth: Shield’s Coverage Expansion and Revenue Potential - TipRanks
Clinical Applications of ctDNA in Colorectal Cancer: Where Do We Stand? - ASCO Daily News
Liquid Biopsy Market Insights and Projections 2025-2032 - openPR
VA expands coverage to include CRC blood test for veterans By Investing.com - Investing.com Australia
VA expands coverage to include CRC blood test for veterans - Investing.com India
Guardant Health shares rise on VA coverage for cancer test By Investing.com - Investing.com South Africa
Guardant Health shares rise on VA coverage for cancer test - Investing.com
Guardant Health’s Shield Blood Test Now Covered for VA Community Care Beneficiaries - Yahoo Finance
Key Market Driver in Breast Cancer Liquid Biopsy Industry 2025: Rising Breast Cancer Cases Fuel Demand For ... - WhaTech
Guardant Health gains amid $292.5M verdict against Natera over false advertising claims (update) - MSN
Guardant Health director Tariq Musa sells $5,069 in stock By Investing.com - Investing.com South Africa
Guardant Health director Tariq Musa sells $5,069 in stock - Investing.com India
1 Healthcare Stock on Our Watchlist and 2 to Turn Down - Yahoo Finance
AI Healthcare Co. Accuses Test-Maker Of Infringing Patents - Law360
AI Health Care Co. Accuses Test-Maker Of Infringing Patents - Law360
Creating awareness for Colorectal Cancer Month - WFLA
Guardant Accused of Infringing Tempus AI Cancer Research Tech - Bloomberg Law News
Guardant Accused of Copying Tempus AI Cancer Research Tech (1) - Bloomberg Law News
Liquid biopsy market flooded with opportunity - BioWorld Online
Guardant Health rises after Medicare ADLT status for colorectal cancer test - MSN
Guardant Health: Great Buy On Dips For Strong Diagnostics Verticals Despite Premium Valuation - Seeking Alpha
Guardant Health at Barclays Conference: Strategic Expansion in Diagnostics By Investing.com - Investing.com UK
Guardant Health’s ADLT Status Boosts Shield CRC Test’s Market Position and Financial Outlook - TipRanks
1,415 Shares in Guardant Health, Inc. (NASDAQ:GH) Bought by SBI Securities Co. Ltd. - Defense World
Investing in Guardant Health (NASDAQ:GH) a year ago would have delivered you a 129% gain - Simply Wall St
Guardant Health Inc Azioni (GH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.05%
0.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):